@article{article_879086, title={Investigation of The Stability of 177LuPSMA-I&T Prostate-specific Membrane Antigen İnhibitor Used in The Treatment of Castration Resistant Prostate Cancer}, journal={Süleyman Demirel Üniversitesi Sağlık Bilimleri Dergisi}, volume={12}, pages={227–232}, year={2021}, DOI={10.22312/sdusbed.879086}, author={Uğur, Ayşe and Gültekin, Aziz}, keywords={Prostata spesifik membran antijeni, PSMA, 177LuPSMA-I&T, kastrasyona dirençli prostat kanseri, radyonüklid tedavisi}, abstract={<p>Objective: Internalization of the prostate-specific membrane antigen (PSMA) by ligand binding through clathrin-coated vesicle followed by endocytosis provides it an excellent target in prostate cancer imaging Gallium-68 (68Ga) and treatment Lutetium-177 (177Lu). The purpose of this research is to examine the in-vitro stability of the radiopharmaceutical (177LuPSMA-I&T) labeled with 177Lu of PSMA-I&T in saline. <br />Material-Method: Labeling of PSMA-I&T with 177Lu was carried out in the automated synthesis module. The labeled 200mCi (7.4 GBq) 177LuPSMA-I&T was incubated at 37oC for 72 hours. Samples taken at regular intervals up to 72 hours were analyzed by radio-high performance liquid chromatography (RP-HPLC). Results: The radiochemical efficiency of 177LuPSMA-I&T was > 99%. We determined that 177LuPSMA-I&T prepared with PSMA-I&T remained stable up to 6 hours, and deteriorated by 3.1% at the 24th hour. Conclusions: With the easy and fast labeled 177LuPSMA-I&T radiopharmaceutical is safe to use in treatment due to its stability in the first 6 hours. <br /> </p>}, number={2}, publisher={Süleyman Demirel Üniversitesi}